Insulet (PODD)
(Delayed Data from NSDQ)
$194.38 USD
-2.38 (-1.21%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $194.51 +0.13 (0.07%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
PODD 194.38 -2.38(-1.21%)
Will PODD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PODD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PODD
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
PODD: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
ESLOY vs. PODD: Which Stock Is the Better Value Option?
Other News for PODD
A Closer Look at 7 Analyst Recommendations For Insulet
Insulet’s Growth Prospects Bolstered by AID Technology and Strategic Market Expansion
Healthcare 2024 Second Half Outlook
$1000 Invested In This Stock 15 Years Ago Would Be Worth $26,000 Today
CereVasc Announces Appointments of New Directors